Immunogenicity of Haemophilus influenzae Type b Tetanus Toxoid Conjugate Vaccine in Young Infants
In a prospective, randomized, double-blind efficacy trial, the immunogenicity of 10 lots of Haemophilus injluenzae type b capsular polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) was evaluated. More than 10,000 infants received PRP-T or hepatitis Bvaccine at about 2, 4, and 6 months of age a...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1994-07, Vol.170 (1), p.76-81 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 81 |
|---|---|
| container_issue | 1 |
| container_start_page | 76 |
| container_title | The Journal of infectious diseases |
| container_volume | 170 |
| creator | Greenberg, David P. Vadheim, Constance M. Partridge, Susan Chang, Swei-Ju Chiu, Chung-Yin Ward, Joel I. |
| description | In a prospective, randomized, double-blind efficacy trial, the immunogenicity of 10 lots of Haemophilus injluenzae type b capsular polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) was evaluated. More than 10,000 infants received PRP-T or hepatitis Bvaccine at about 2, 4, and 6 months of age along with other childhood vaccines. In a subset of infants, geometric mean concentrations of total anticapsular antibody were 0.08, 0.79, and 5.29 µg/mL after the first, second, and third doses, respectively. Four lots of reconstituted lyophilized PRP-T vaccine were significantly more immunogenic than 6 lots of aqueous vaccine (P = .03). In a stepwise regression model, the most important additional factors affecting anticapsular antibody concentrations were the time between the third dose and the blood draw, race, and breast-feeding status at 6 months of age. Immune responses to diphtheria and tetanus toxoids were not significantly different for infants given PRP-T or hepatitis Bvaccines along with diphtheria-tetanus toxoid-pertussis vaccine. |
| doi_str_mv | 10.1093/infdis/170.1.76 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_16656750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30133477</jstor_id><sourcerecordid>30133477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2060-3da8e6fc09b641bbfd4d02239cd8ec45fc28b260e84bf362d0834948d3f4105b3</originalsourceid><addsrcrecordid>eNo9kEFr2zAYhsVYYVnX804FHcZubj5ZsmQfR1ibQKBdccu2i5BlKVVmS6llQ9NfXxV3PYmP53lfxIvQVwIXBCq6dN62Li6JSPeF4B_QghRUZJwT-hEtAPI8I2VVfUKfY9wDAKNcLJDa9P3kw854p914xMHitTJ9ODy4boo4lXaT8c_K4Pp4MLjBtRmVT6QOT8G1eBX8ftqp0eB7pbXzJkXwnzD5Hd54q_wYv6ATq7pozt7eU3R3-bNerbPt9dVm9WOb6Rw4ZLRVpeFWQ9VwRprGtqxNf6aVbkujWWF1XjY5B1OyxlKet1BSVrGypZYRKBp6ir7PvYchPE4mjrJ3UZuuU96EKUrCecFFAUlczqIeQoyDsfIwuF4NR0lAvk4p5yllmlISKXhKfHurVlGrzg7K68T_xxgpc6Aiaeezto9jGN4xBUIpE688m7mLo3l652r4J7mgopDr33_lLfy6v9leXsmavgCNVY81</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16656750</pqid></control><display><type>article</type><title>Immunogenicity of Haemophilus influenzae Type b Tetanus Toxoid Conjugate Vaccine in Young Infants</title><source>Jstor Complete Legacy</source><creator>Greenberg, David P. ; Vadheim, Constance M. ; Partridge, Susan ; Chang, Swei-Ju ; Chiu, Chung-Yin ; Ward, Joel I.</creator><creatorcontrib>Greenberg, David P. ; Vadheim, Constance M. ; Partridge, Susan ; Chang, Swei-Ju ; Chiu, Chung-Yin ; Ward, Joel I. ; Kaiser-UCLA Vaccine Study Group ; Kaiser-UCLA Vaccine Study Grou</creatorcontrib><description>In a prospective, randomized, double-blind efficacy trial, the immunogenicity of 10 lots of Haemophilus injluenzae type b capsular polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) was evaluated. More than 10,000 infants received PRP-T or hepatitis Bvaccine at about 2, 4, and 6 months of age along with other childhood vaccines. In a subset of infants, geometric mean concentrations of total anticapsular antibody were 0.08, 0.79, and 5.29 µg/mL after the first, second, and third doses, respectively. Four lots of reconstituted lyophilized PRP-T vaccine were significantly more immunogenic than 6 lots of aqueous vaccine (P = .03). In a stepwise regression model, the most important additional factors affecting anticapsular antibody concentrations were the time between the third dose and the blood draw, race, and breast-feeding status at 6 months of age. Immune responses to diphtheria and tetanus toxoids were not significantly different for infants given PRP-T or hepatitis Bvaccines along with diphtheria-tetanus toxoid-pertussis vaccine.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/170.1.76</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Antibodies ; Bacterial diseases ; Bacterial diseases of the respiratory system ; Biological and medical sciences ; Children ; Clostridium tetani ; Conjugate vaccines ; Dosage ; Gestational age ; Haemophilus influenzae ; Haemophilus influenzae type b ; Human bacterial diseases ; Immune response ; Infants ; Infectious diseases ; Major Articles ; Medical sciences ; Tetanus toxoid ; Vaccination</subject><ispartof>The Journal of infectious diseases, 1994-07, Vol.170 (1), p.76-81</ispartof><rights>Copyright 1994 The University of Chicago</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2060-3da8e6fc09b641bbfd4d02239cd8ec45fc28b260e84bf362d0834948d3f4105b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30133477$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30133477$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,777,781,800,27905,27906,57998,58231</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4182037$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Greenberg, David P.</creatorcontrib><creatorcontrib>Vadheim, Constance M.</creatorcontrib><creatorcontrib>Partridge, Susan</creatorcontrib><creatorcontrib>Chang, Swei-Ju</creatorcontrib><creatorcontrib>Chiu, Chung-Yin</creatorcontrib><creatorcontrib>Ward, Joel I.</creatorcontrib><creatorcontrib>Kaiser-UCLA Vaccine Study Group</creatorcontrib><creatorcontrib>Kaiser-UCLA Vaccine Study Grou</creatorcontrib><title>Immunogenicity of Haemophilus influenzae Type b Tetanus Toxoid Conjugate Vaccine in Young Infants</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>In a prospective, randomized, double-blind efficacy trial, the immunogenicity of 10 lots of Haemophilus injluenzae type b capsular polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) was evaluated. More than 10,000 infants received PRP-T or hepatitis Bvaccine at about 2, 4, and 6 months of age along with other childhood vaccines. In a subset of infants, geometric mean concentrations of total anticapsular antibody were 0.08, 0.79, and 5.29 µg/mL after the first, second, and third doses, respectively. Four lots of reconstituted lyophilized PRP-T vaccine were significantly more immunogenic than 6 lots of aqueous vaccine (P = .03). In a stepwise regression model, the most important additional factors affecting anticapsular antibody concentrations were the time between the third dose and the blood draw, race, and breast-feeding status at 6 months of age. Immune responses to diphtheria and tetanus toxoids were not significantly different for infants given PRP-T or hepatitis Bvaccines along with diphtheria-tetanus toxoid-pertussis vaccine.</description><subject>Antibodies</subject><subject>Bacterial diseases</subject><subject>Bacterial diseases of the respiratory system</subject><subject>Biological and medical sciences</subject><subject>Children</subject><subject>Clostridium tetani</subject><subject>Conjugate vaccines</subject><subject>Dosage</subject><subject>Gestational age</subject><subject>Haemophilus influenzae</subject><subject>Haemophilus influenzae type b</subject><subject>Human bacterial diseases</subject><subject>Immune response</subject><subject>Infants</subject><subject>Infectious diseases</subject><subject>Major Articles</subject><subject>Medical sciences</subject><subject>Tetanus toxoid</subject><subject>Vaccination</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><recordid>eNo9kEFr2zAYhsVYYVnX804FHcZubj5ZsmQfR1ibQKBdccu2i5BlKVVmS6llQ9NfXxV3PYmP53lfxIvQVwIXBCq6dN62Li6JSPeF4B_QghRUZJwT-hEtAPI8I2VVfUKfY9wDAKNcLJDa9P3kw854p914xMHitTJ9ODy4boo4lXaT8c_K4Pp4MLjBtRmVT6QOT8G1eBX8ftqp0eB7pbXzJkXwnzD5Hd54q_wYv6ATq7pozt7eU3R3-bNerbPt9dVm9WOb6Rw4ZLRVpeFWQ9VwRprGtqxNf6aVbkujWWF1XjY5B1OyxlKet1BSVrGypZYRKBp6ir7PvYchPE4mjrJ3UZuuU96EKUrCecFFAUlczqIeQoyDsfIwuF4NR0lAvk4p5yllmlISKXhKfHurVlGrzg7K68T_xxgpc6Aiaeezto9jGN4xBUIpE688m7mLo3l652r4J7mgopDr33_lLfy6v9leXsmavgCNVY81</recordid><startdate>19940701</startdate><enddate>19940701</enddate><creator>Greenberg, David P.</creator><creator>Vadheim, Constance M.</creator><creator>Partridge, Susan</creator><creator>Chang, Swei-Ju</creator><creator>Chiu, Chung-Yin</creator><creator>Ward, Joel I.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>19940701</creationdate><title>Immunogenicity of Haemophilus influenzae Type b Tetanus Toxoid Conjugate Vaccine in Young Infants</title><author>Greenberg, David P. ; Vadheim, Constance M. ; Partridge, Susan ; Chang, Swei-Ju ; Chiu, Chung-Yin ; Ward, Joel I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2060-3da8e6fc09b641bbfd4d02239cd8ec45fc28b260e84bf362d0834948d3f4105b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Antibodies</topic><topic>Bacterial diseases</topic><topic>Bacterial diseases of the respiratory system</topic><topic>Biological and medical sciences</topic><topic>Children</topic><topic>Clostridium tetani</topic><topic>Conjugate vaccines</topic><topic>Dosage</topic><topic>Gestational age</topic><topic>Haemophilus influenzae</topic><topic>Haemophilus influenzae type b</topic><topic>Human bacterial diseases</topic><topic>Immune response</topic><topic>Infants</topic><topic>Infectious diseases</topic><topic>Major Articles</topic><topic>Medical sciences</topic><topic>Tetanus toxoid</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Greenberg, David P.</creatorcontrib><creatorcontrib>Vadheim, Constance M.</creatorcontrib><creatorcontrib>Partridge, Susan</creatorcontrib><creatorcontrib>Chang, Swei-Ju</creatorcontrib><creatorcontrib>Chiu, Chung-Yin</creatorcontrib><creatorcontrib>Ward, Joel I.</creatorcontrib><creatorcontrib>Kaiser-UCLA Vaccine Study Group</creatorcontrib><creatorcontrib>Kaiser-UCLA Vaccine Study Grou</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Greenberg, David P.</au><au>Vadheim, Constance M.</au><au>Partridge, Susan</au><au>Chang, Swei-Ju</au><au>Chiu, Chung-Yin</au><au>Ward, Joel I.</au><aucorp>Kaiser-UCLA Vaccine Study Group</aucorp><aucorp>Kaiser-UCLA Vaccine Study Grou</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of Haemophilus influenzae Type b Tetanus Toxoid Conjugate Vaccine in Young Infants</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1994-07-01</date><risdate>1994</risdate><volume>170</volume><issue>1</issue><spage>76</spage><epage>81</epage><pages>76-81</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>In a prospective, randomized, double-blind efficacy trial, the immunogenicity of 10 lots of Haemophilus injluenzae type b capsular polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) was evaluated. More than 10,000 infants received PRP-T or hepatitis Bvaccine at about 2, 4, and 6 months of age along with other childhood vaccines. In a subset of infants, geometric mean concentrations of total anticapsular antibody were 0.08, 0.79, and 5.29 µg/mL after the first, second, and third doses, respectively. Four lots of reconstituted lyophilized PRP-T vaccine were significantly more immunogenic than 6 lots of aqueous vaccine (P = .03). In a stepwise regression model, the most important additional factors affecting anticapsular antibody concentrations were the time between the third dose and the blood draw, race, and breast-feeding status at 6 months of age. Immune responses to diphtheria and tetanus toxoids were not significantly different for infants given PRP-T or hepatitis Bvaccines along with diphtheria-tetanus toxoid-pertussis vaccine.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><doi>10.1093/infdis/170.1.76</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1994-07, Vol.170 (1), p.76-81 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16656750 |
| source | Jstor Complete Legacy |
| subjects | Antibodies Bacterial diseases Bacterial diseases of the respiratory system Biological and medical sciences Children Clostridium tetani Conjugate vaccines Dosage Gestational age Haemophilus influenzae Haemophilus influenzae type b Human bacterial diseases Immune response Infants Infectious diseases Major Articles Medical sciences Tetanus toxoid Vaccination |
| title | Immunogenicity of Haemophilus influenzae Type b Tetanus Toxoid Conjugate Vaccine in Young Infants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A01%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20Haemophilus%20influenzae%20Type%20b%20Tetanus%20Toxoid%20Conjugate%20Vaccine%20in%20Young%20Infants&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Greenberg,%20David%20P.&rft.aucorp=Kaiser-UCLA%20Vaccine%20Study%20Group&rft.date=1994-07-01&rft.volume=170&rft.issue=1&rft.spage=76&rft.epage=81&rft.pages=76-81&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/170.1.76&rft_dat=%3Cjstor_proqu%3E30133477%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16656750&rft_id=info:pmid/&rft_jstor_id=30133477&rfr_iscdi=true |